BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 16932434)

  • 21. [Case of early pronounced anemia and its effective treatment with human recombinant erythropoietin in a female patient with polycystic kidney in a conservative stage of chronic renal failure].
    Alekseeva TB; Nikolaev AIu; Trofimova EI
    Ter Arkh; 1999; 71(6):70-1. PubMed ID: 10420463
    [No Abstract]   [Full Text] [Related]  

  • 22. Target hemoglobin level for EPO therapy in CKD.
    Parfrey PS
    Am J Kidney Dis; 2006 Jan; 47(1):171-3. PubMed ID: 16377399
    [No Abstract]   [Full Text] [Related]  

  • 23. [Is the management of anemia in hemodialysis patients improving in France? Results of the DiaNE study].
    Kessler M; Landais P; Canivet E; Yver L; Bataille P; Brillet G; Commenges B; Koné S
    Nephrol Ther; 2009 Apr; 5(2):114-21. PubMed ID: 19042175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [How to optimize the concept of the variability of haemoglobin in dialysis patients].
    Kessler M
    Nephrol Ther; 2008 Dec; 4(7):547-8. PubMed ID: 18809370
    [No Abstract]   [Full Text] [Related]  

  • 25. Erythropoietin and its use in renal failure.
    Sulková S; Krajhanzl A
    EDTNA ERCA J; 1996; 22(1):suppl 1-7; quiz 8. PubMed ID: 10723310
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adherence to guidelines for ESRD anemia management.
    Hynes DM; Stroupe KT; Kaufman JS; Reda DJ; Peterman A; Browning MM; Huo Z; Sorbara D
    Am J Kidney Dis; 2006 Mar; 47(3):455-61. PubMed ID: 16490624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of renal anemia with intravenous erythropoietin in patients in the program of continuous ambulatory peritoneal dialysis].
    Zelichowski G; Lubas A; Sienkiewicz M; Janusz E; Wańkowicz Z
    Pol Merkur Lekarski; 2008 Apr; 24(142):312-5. PubMed ID: 18634362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients.
    Besarab A; Reyes CM; Hornberger J
    Am J Kidney Dis; 2002 Sep; 40(3):439-46. PubMed ID: 12200793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What is needed to achieve a hemoglobin of 11.0-13.0 g/dl in end-stage renal disease.
    Fishbane S
    Blood Purif; 2007; 25(1):53-7. PubMed ID: 17170538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Erythropoietin and renal failure.
    Macdougall IC
    Curr Hematol Rep; 2003 Nov; 2(6):459-64. PubMed ID: 14561389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anemia in renal insufficiency.
    Santoro A
    Rev Clin Exp Hematol; 2002; Suppl 1():12-20. PubMed ID: 12735211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secondary hyperparathyroidism as cause of resistance to treatment with erythropoietin: effect of parathyroidectomy.
    Goicoechea M; Gomez-Campdera F; Polo JR; Tejedor A; Ruiz MA; Vazquez I; Verde E; Valderrabano F
    Clin Nephrol; 1996 Jun; 45(6):420-1. PubMed ID: 8793241
    [No Abstract]   [Full Text] [Related]  

  • 33. [Erythropoietin drugs in patients with chronic renal failure at the stage of conservative treatment. Effectiveness and side effects].
    Alekseeva TB; Nikolaev AIu; Dasaeva LA
    Ter Arkh; 2000; 72(6):58-60. PubMed ID: 10900653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The pharmacokinetics of recombinant human erythropoietin].
    Siniukhin VN; Stetsiuk EA; Lovchinskiĭ EV; Lebedev SV; Iarmolinskiĭ IS; Liakhov VV
    Ter Arkh; 1994; 66(8):60-2. PubMed ID: 7985158
    [No Abstract]   [Full Text] [Related]  

  • 35. High-dose folic acid supplements and responsiveness to rHu-EPO in HD patients.
    Sepe V; Adamo G; Giuliano MG; Soccio G; Libetta C; Dal Canton A
    Nephrol Dial Transplant; 2006 Jul; 21(7):2036. PubMed ID: 16504977
    [No Abstract]   [Full Text] [Related]  

  • 36. The EPO/iron marriage: counseling needed.
    Bralow S
    Nephrol News Issues; 2007 Jun; 21(7):53, 55. PubMed ID: 17623987
    [No Abstract]   [Full Text] [Related]  

  • 37. The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalization.
    Silverberg DS; Wexler D; Blum M; Tchebiner J; Sheps D; Keren G; Schwartz D; Baruch R; Yachnin T; Shaked M; Zubkov A; Steinbruch S; Iaina A
    Clin Nephrol; 2002 Jul; 58 Suppl 1():S37-45. PubMed ID: 12227725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. To treat or not to treat renal anemia of chronic kidney disease patients?
    Tsubakihara Y
    Ther Apher Dial; 2010 Jun; 14(3):235-9. PubMed ID: 20609177
    [No Abstract]   [Full Text] [Related]  

  • 39. [Therapeutic guidelines for renal anemia in Japan].
    Naito M; Akiba T
    Nihon Rinsho; 2004 Jun; 62 Suppl 6():562-5. PubMed ID: 15250369
    [No Abstract]   [Full Text] [Related]  

  • 40. [Anemia in chronic renal failure and erythropoietin].
    Rosenlöf K
    Duodecim; 1995; 111(15):1489-95. PubMed ID: 9244705
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.